Compounds for medicinal use

• US 5,877,147 A
• Filed: 07/29/1996
• Issued: 03/02/1999
• Est. Priority Date: 10/08/1993
• Status: Expired due to Fees

• Current Assignee: Peptech Limited (Teva Pharmaceutical Industries Limited)
• Original Assignee: Peptech (UK) Limited
• Inventors: Pinegin, Boris Vladimirovich
• Primary Examiner(s): Tsang, Cecilia J.
• Assistant Examiner(s): CELSA, BENNETT M
• Application Number:
  US08/624,592
• Time in Patent Office: 946 Days
• Field of Search: 530/322, 514/8, 514/17, 424/117, 260/112.5
• US Class Current: 424/279.1
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Muramyl peptide compounds are useful in the prophylaxis of cancers and particularly in the treatment of precancerous lesions associated with cancers of the mucosa or epithelium.

Claims

1. A method for the treatnent of a precancerous lesion leading to a mucosal or epithelal cancer, comprising administering to a patient suffiering from said precancerous lesion an effective amount of a muramyl peptide compound of low intrnsic pyrogenicity.

3. The method of claims 1 or 2, wherein said cancer is cervical cancer, colorectal cancer, cancer of the anus, basal or squamous cell carcinoma, melanoma, penile squamous carcinoma, cancer of the penis, cancer of the vulva, cancer of the oral mucosa, gastric cancer, bladder carcinoma, or oesophageal squamous cell carcinoma.

4. The method of claim 1 or claim 2, wherein said muramyl peptide compound is administered in combination with surgery, chemotherapy, immunotherapy or radiation therapy.

5. The method of claim 1 or 2, wherein said muramyl peptide compound is N-acetylmuramyl-L-threonyl-D-isoglutamine (Thr-MDP) or N-acetylmuramyl-L-alanyl-D-glutamine n-butyl ester (Murabutide).

6. The method of claim 1 or claim 2, wherein the muramyl peptide compound is a compound of general formula II:

##STR25## wherein;

R represents an amino acid residue or a linear peptide built of from 2 to 6 amio acid residues, at least onae of the residues being optionally substituted with a lipophilic group; and

n is 1 or b 2;

or an anomer thereof.

7. The method of claim 6, wherein n is 1.

8. The method of claim 6, wherein the amiino acid residue is a residue of an L-ainio acid.

9. The method of claim 8, wherein the amino acid residue is a residue of L-alanie.

10. The method of claim 6, wherein the second amino acid residue in said linear peptide, if present, is of the D-configuration.

11. The method of claim 10, wherein said second amino acid residue is a residue of D-glutamic or D-aspartic acid or a mono-, di- or mixed C₁ -C₂₂ alkyl ester, amide or C₁ -C₄ alkyl amide thereof.

12. The method of claim 11, wherein said mixed alkyl ester is a C₁ -C₆ alkyl ester.

13. The method of claim 10, wherein the second omino acid residue is D-isoglutaminyl or D-glutamyl.

14. The method of claim 6, wherein the third amino acid residue in said linear peptide, if present, if present, is of the L-configuration.

15. The method of claim 14, wherein said third amino acid residue is L-alanyl or L-lysyl.

16. The method of claim 6, wherein said amino acid residue or linear peptide is substituted with a lipophilic group.

17. The method of claim 6, wherein said compound is N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-isoglutainie (GMDP).

18. The method of claim 6, wherein the compound is:

N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-glutamic acid (GMDP-A);

N-acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-L-alanyl-D-glutamine n-butyl ester (GMDP-OBu);

N- Nα

-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-L-alanyl-D-isoglutaminyl !-N.sup.≢

-stearoyl-L-lysine (GMDP-Lys(St));

N.sup.α

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetyl-muramyl-L-alanyl-γ

-D-glutamyl !-N.sup.≢

-stearoyl-L-lysine (GMDPA-Lys(St));

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid dibenzyl ester (GMDPA(OBzi)₂);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-N-methyl-L-alanyl-D-isoglutamine (Me-GMDP);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-(β

1-4)-N-acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-bis-(L-alanyl-D-isoglutamine) ((GMDP)₂);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-(β

1-4)-N-acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-bis-(L-alanyl-D-glutamic acid) ((GMDPA) ₂);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-(β

1-4)-N-acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-bis-(L-alanyl-D-isoglutaminyl-L-lysine) ((GMDP Lys)₂);

N-acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-(β

1-4)-N-acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-bis- L-alanyl-D-isoglutaminyl-N.sup.≢

-stearoyl-L-lysine! ( GMDP-Lys(St)! ₂);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine 1-adamantyl ester (GMDP-Ad);

L-Threonyl-N.sup.≢

- N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetyl-muramyl-L-alanyl-γ

-D-isoglutaminyl ! -L-lysyl-L-prolyl-L-arginine (GMDP-tuftsin E);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetyl-muramyl-L-alanyl-γ

-D-isoglutaminyl-L-threonyl-L-lysyl-L-prolyl-L-arginine (GMDP-tuftsin A);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-L-alanyl-α

-D-glutamyl -L-lysyl-L-threonyl -N.sup.≢

-stearoyl-L-lysyl-L-prolyl-L-arginine (GMDPA-tuftsin lipophilic);

N.sup.≢

- N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetyl-muramyl-L-alanyl-γ

-D-isoglutaminyl !-L-lysyl-L-histidyl-L-glycine amide (GMDPA-bursin);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-glutamyl-L-tryptophan (GMDP-thymogen I);

N-Acetyl-D-glucosaminyl-(β

1-4)-N-acetylmuramyl-L-alanyl-D-isoglutaminyl-ε

-aminohexanoyl-L-glutamyl-L-tryptophan (GMDP-thymogen II);

or N⁶⁰ - N-acetyl-D-glucosaminyl-(β

1-4)-N-acetyl-muramyl-L-alanyl-D-isoglutaninyl !-N.sup.ε

-stearoyl-L-lysyl-L-glutamyl-L-tryptophan (GMDP-thymogen III).

19. The method of claim 1 or claim 2, wherein the muramyl peptide compound is administered via the oral, vaginal, rectal, topical, transdermal or parenteral route.

2. A method for the prophylaxis of a skin cancer, comprising administering to a patient an effective amount of a muramyl peptide compound.